Filing Details

Accession Number:
0001209191-19-003315
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-10 18:08:04
Reporting Period:
2019-01-09
Accepted Time:
2019-01-10 18:08:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1604464 Atara Biotherapeutics Inc. ATRA Biological Products, (No Disgnostic Substances) (2836) 460920988
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1612096 E. Isaac Ciechanover 611 Gateway Boulevard
Suite 900
South San Francisco CA 94080
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-01-09 1,900 $34.51 9,978 No 4 S Indirect See footnote
Common Stock Disposition 2019-01-09 2,000 $35.16 7,978 No 4 S Indirect See footnote
Common Stock Disposition 2019-01-10 1,700 $33.93 6,278 No 4 S Indirect See footnote
Common Stock Disposition 2019-01-10 2,200 $34.50 4,078 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 733,285 Direct
Footnotes
  1. Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
  2. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.97 to $34.905. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
  4. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.99 to $35.43. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.36 to $34.36. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.38 to $34.68. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.